期刊文献+

插植调强近距离放疗复发宫颈癌的同期对照研究 被引量:4

The Concurrent Control Study of Implanted Intensity Modulated Brachytherapy for Recurred Cervical Carcinoma
在线阅读 下载PDF
导出
摘要 目的:探讨插植调强近距离放疗在复发宫颈癌中的价值。方法:25例盆腔复发宫颈癌患者行插植后装调强近距离放疗为实验组,选择同期行常规后装放疗的25例盆腔复发宫颈癌患者作为对照组,比较两组间的近期疗效及合并症。结果:实验组完全缓解20例,部分缓解5例,对照纽完全缓解10例,部分缓解7例,稳定4例,进展4例,差异有统计学意义(P=0.005)。实验组出现5例阴道直肠瘘,1例3级肠炎;对照组出现3例阴道直肠瘘,1例3级肠炎。结论:盆腔插植调强近距离放疗治疗复发宫颈癌近期疗效满意,优于常规近距离放疗,毒副反应可耐受。 Objective: To explore the value of implanted intensity-modulated brachytherapy for recurred cervical carcinoma. Methods: A total of 25 cases of recurred cervical carcinoma were enrolled into the trial group which were treated with pelvic implanted afterloading intensity-modulated brachytherapy. The other 25 patients with recurred cervical carcinoma treated with routine brachytherapy during the same period were enrolled into the control group. Results: There were 20 cases with CR and 5 cases with PR in the trial group, and 10 cases with CR, 7 cases with PR, 4 cases with SD and 4 cases with PD in the control group, with a significant difference between the two groups (P〈0.05). In the trial group, there were 5 cases with vaginal-rectal fistula and 1 case with grade 3 enteritis. In the control group, there were 3 cases with vaginal-rectal fistula. Conclusion: Pelvic implanted intensity-modulated brachytherapy for recurred cervical carcinoma is satisfactory with better short-term efficacy than that of the routine brachytherapy and tolerable side effects.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2009年第21期1219-1222,共4页 Chinese Journal of Clinical Oncology
关键词 宫颈肿瘤 治疗 近距离放疗 调强放疗 Cervical neoplasms Therapy Brachytherapy Intensity modulated radiotherapy
  • 相关文献

参考文献10

  • 1杨晓霞,韩云青.24例复发宫颈癌的化疗疗效分析[J].医药论坛杂志,2005,26(9):32-33. 被引量:4
  • 2闻强,朱笕青.晚期或复发宫颈癌化疗进展[J].国外医学(妇产科学分册),2007,34(3):180-183. 被引量:8
  • 3Viswanathan AN. The Frank Ellis memorial lecture: the use of three-dimensional imaging in gynaecological radiation therapy[J].Clin Oncol(R Coil Radiol), 2008, 20(1): 1-5.
  • 4Potter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group ( II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy,-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology[J]. Radiother Oncol, 2006, 78(1): 67-77.
  • 5Tan LT, Coles CE, Hart C, et al. Clinical impact of computed tomography-based image-guided brachytherapy for cervix cancer using the tandem-ring applicator-the Addenbrooke's experience [J]. Clin Oncol(R Coll Radiol), 2009, 21(3): 175-182.
  • 6Lessard E, Hsu IC, PouliotJ. Inverse planning for interstitial gynecologic template brachytherapy: truly anatomy-based planning[J]. IntJ Radiat Oncol Biol Phys, 2002, 54(4): 1243-1251.
  • 7Charra C, Roy P, Coquard R, et al. Outcome of treatment of upper third vaginal recurrences of cervical and endometrial carcinomas with interstitial brachytherapy[J]. Int J Radiat Oncol Biol Phys. 1998, 40(2): 421-426.
  • 8Sharma DN, Subramani V, Rath GK, et al. Interstitial brachyther apy guided intensity modulated radiation therapy in cervical carci noma: a dosimetric study[J]. IntJ Radiat Oncol Biol Phys, 2007 69(3): S731-S732.
  • 9Georg D, Kirisits C, Hillbrand M, et al. Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2008, 71(4): 1272-1278.
  • 10Cengiz M, Gurdalli S, Selek U, et al. Effect of bladder distension on dose distribution of intracavitary brachytherapy for cervical canccr computed tomography plan evaluation[J]. IntJ Radiat Oncol Biol Phys, 2008, 70(2): 464-468.

二级参考文献26

  • 1连利娟 林巧稚.妇科肿瘤学2版[M].北京:人民卫生出版社,1994.353.
  • 2Slchenm yer WJ, Row insky EK, Donehower RC, et al. The current status of camptothecin anatogues as antitum or agents. J National Cancer Institute, 1993,85 (4) :271.
  • 3Panayotis P. Preclinical studies of water insoluable camptothecin congeners, cytotoxicity, development of resistance,and combination treatment. Clinical Cancer Research,1995,1 : 1235.
  • 4Salecm A, Ibrablm N, Patel M, et al. Mechanism of resistance in a human cell the exposed to sequential topoismerese poisoning. Cancer Res, 1997,57 : 5100.
  • 5Megonigal MD, Fertala J, Bjornsti MA. Alteration in the catalytic activity of yeast DNA toposiomerase I result in cell cycle arrest and cel death. J B jol Chem, 1997,272:12801.
  • 6上海市药物研究所.羟基喜素硷的实验治疗和毒性[J].中国肿瘤临床,2000,27:37-37.
  • 7Fracasso PM,Blessing JA,Wolf J,et al.Phase Ⅱ evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix:a gynecologic oncology group study[J].Gynecol Oncol,2003,90(1):177-180.
  • 8Schilder RJ,Blessing JA,Morgan M,et al.Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix:a Phase Ⅱstudy of the gynecologic oncology group[J].Gynecol Oncol,2004,94(2):483-487.
  • 9Schilder RJ,Blessing J,Cohn DE,et al.Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix:a phase Ⅱ study of the Gynecologic Oncology Group[J].Gynecol Oncol,2005,96(1):103-107.
  • 10Muggia FM,Blessing JA,Method M,et al.Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix:a Gynecologic Oncology Group study[J].Gynecol Oncol,2004,92(2):639-643.

共引文献8

同被引文献25

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部